The critical role of comorbidities and polypharmacy in lower risk myelodysplastic patients: is there any difference between countries?

Med Oncol. 2018 Sep 11;35(11):143. doi: 10.1007/s12032-018-1205-5.

Authors

Priscila da Silva Mendonça¹, Ronald Pinheiro Feitosa², Silvia Maria Meira Magalhães²

Affiliations

¹ Cancer Cytogenomic Laboratory, Post-graduate Program in Medical Science, Federal University of Ceara, R. Coronel Nunes de Melo, 1000 - 2° andar - Rodolfo Teófilo, Fortaleza, CE, CEP 60430-275, Brazil. n.priscilas@gmail.com.
² Cancer Cytogenomic Laboratory, Post-graduate Program in Medical Science, Federal University of Ceara, R. Coronel Nunes de Melo, 1000 - 2° andar - Rodolfo Teófilo, Fortaleza, CE, CEP 60430-275, Brazil.

PMID: 30206716
DOI: 10.1007/s12032-018-1205-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Comorbidity*
Humans
Polypharmacy*
Risk